Amrutanjan Health Care Ltd plans to offer custom manufacturing services through its fine chemicals subsidiary, Amrutanjan Pharmaessence Pvt Ltd. The company has signed a memorandum of understanding to provide contract manufacturing for Sigma Aldrich.
Business Standard
Thursday, 22 September 2011
Amrutanjan to start custom manufacturing
Tuesday, 20 September 2011
Lonza plans Singapore listing
Lonza will list on the Singapore stock exchange later this year. The secondary listing on the Main Board of the Singapore Exchange Securities Trading Limited is designed to give the company a more visible presence in Asia, allowing it to tap the strong capital flows in Asia, and enlarging and broadening its current investor base in the region, said Stehan Borgas, Lonza's ceo.
Channel News Asia
Thursday, 15 September 2011
Jubilant's $70m contract
Jubilant Life Sciences' Jubilant HollisterStier facility in Montreal, Canada, will manufacture a product for a US pharma company. The deal is worth $70m over the next four years. Economic Times
Warning letter for Lonza
Lonza has received an FDA warning letter following cGMP violations in the production of Eisai's Ontak at its Hopkinton, MA, facility. Lonza received the letter after failing to address issues raised in inspections during April and May. The FDA cited Lonza for inadequate or lack of an investigation of critical deviations or a failure of a batch to meet its specifications or quality standards; failure to validate analytical test methods used for API for potency testing; and failure of its quality unit to exercise its responsibility to ensure that APIs manufactured are in compliance with CGMP, including meeting established specifications for quality and purity. In-pharma Technologist
Monday, 12 September 2011
Wednesday, 7 September 2011
Lonza and Fosun to establish jv
Lonza and Shanghai Fosun Pharmaceutical plan to create a jv in Pudong Zhangjiang High-Tech Industry Zone. The two companies will jointly invest CNY100m ($15.6m). Lonza has said that five drugs will be produced by the jv. Capital Vue
Fareva acquires Pfizer plant
Fareva has acquired Pfizer's Henrico, VA, plant and will invest $42m in the facility. Fareva will keep the current 500 employees at the facility and planes to add more over the next five years. As part of the agreement, Fareva will manufacture products for Pfizer for six years. Richmond Times-Dispatch
DSM and Sinochem anti-infectives jv
DSM has established a Hong Kong-based 50/50 global joint venture for its business anti-Iinfectives with Sinochem. Under the jv agreement Sinochem has paid €210m for a 50% equity interest in the business group. The new organisation will be called DSM Sinochem Pharmaceuticals Limited. DSM
Sales grow for Siegfried
Siegfried reported a 28.3% rise in sales to CHF173.8m in H1 2011. Siegfried attributed the growth to a significant increase in API sales, particularly in exclusive synthesis. The company said its strategy is on track and it has the necessary funds for implementation of the strategy. Siegfried
Subscribe to:
Posts (Atom)
